Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma - CEP-2

NCT05100628 is registered in ClinicalTrials.gov with Noxopharm Limited as lead sponsor.

NCT NCT05100628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05100628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma - CEP-2
Lead sponsor
Noxopharm Limited
Phase
Phase 1
Overall status
Terminated
Start date
February 11, 2022
Completion date
May 26, 2023
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic soft-tissue sarcoma